Stuttgart - Delayed Quote EUR

Syndax Pharmaceuticals Inc (1T3.SG)

19.10 +0.20 (+1.06%)
At close: April 26 at 10:32 AM GMT+2
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
--
--
--
139,709.00
1,517.00
Operating Expense
229,954.00
229,954.00
151,757.00
113,489.00
72,940.00
Operating Income
-229,954.00
-229,954.00
-151,757.00
26,220.00
-71,423.00
Net Non Operating Interest Income Expense
20,955.00
20,955.00
2,735.00
-1,496.00
-1,516.00
Other Income Expense
-361.00
-361.00
-316.00
202.00
-219.00
Pretax Income
-209,360.00
-209,360.00
-149,338.00
24,926.00
-73,158.00
Net Income Common Stockholders
-209,360.00
-209,360.00
-149,338.00
24,926.00
-77,064.00
Diluted NI Available to Com Stockholders
-209,360.00
-209,360.00
-149,338.00
24,926.00
-77,064.00
Basic EPS
-2.59
-2.98
-2.46
0.48
-1.87
Diluted EPS
-2.59
-2.98
-2.46
0.48
-1.87
Basic Average Shares
68,039.28
70,370.52
60,760.91
52,064.81
41,308.24
Diluted Average Shares
68,039.28
70,370.52
60,760.91
52,064.81
41,308.24
Total Operating Income as Reported
-229,954.00
-229,954.00
-151,757.00
26,220.00
-71,423.00
Total Expenses
229,954.00
229,954.00
151,757.00
113,489.00
72,940.00
Net Income from Continuing & Discontinued Operation
-209,360.00
-209,360.00
-149,338.00
24,926.00
-73,158.00
Normalized Income
-209,360.00
-209,360.00
-149,338.00
24,926.00
-73,158.00
Interest Income
21,163.00
21,163.00
5,872.00
403.00
841.00
Interest Expense
208.00
208.00
3,137.00
1,899.00
2,357.00
Net Interest Income
20,955.00
20,955.00
2,735.00
-1,496.00
-1,516.00
EBIT
-209,152.00
-209,152.00
-146,201.00
26,825.00
-70,801.00
EBITDA
-209,140.00
-209,140.00
-146,168.00
26,868.00
-70,712.00
Reconciled Depreciation
12.00
12.00
33.00
43.00
89.00
Net Income from Continuing Operation Net Minority Interest
-209,360.00
-209,360.00
-149,338.00
24,926.00
-73,158.00
Normalized EBITDA
-209,140.00
-209,140.00
-146,168.00
26,868.00
-70,712.00
12/31/2020 - 8/28/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

2CL.F BridgeBio Pharma, Inc.
22.83
+3.26%
 
XUPB.F Genfit S.A.
3.0800
-1.28%
 
1GDA.BE Zevra Therapeutics Inc
4.2400
+0.95%
 
CAMXs.XC
 
AB3A.BE Sarepta Therapeutics Inc
118.45
+2.82%
 
1AE.SG argenx SE
343.70
-0.75%
 
GNFTF Genfit S.A.
2.9500
0.00%
 
20D.F Cidara Therapeutics, Inc.
0.4780
0.00%
 
UNC.MU UCB SA
124.65
+4.31%
 
2H51.MU Ocugen Inc
1.1460
-1.55%